Evidence map›Paper›PMID 41509313›Full record

ArticlebioRxiv : the preprint server for biology2025

Assessment of Imaging Mass Cytometry (IMC) as a Tool to Characterize Circulating Tumor Cells (CTCs) in Preclinical Mouse Models.

Milind Pore, Kuppusamy Balamurugan, Abigail Atkinson, Devynn Breen, Paul Mallory, Ashley Cardamone, Lois McKennett, Christine Newkirk, Shikha Sharan, William Bocik and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Milind PoreImaging Mass Cytometry Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA.ORCID 0000-0001-6513-653X
Kuppusamy BalamuruganCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.ORCID 0000-0002-6010-080X
Abigail AtkinsonImaging Mass Cytometry Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA.
Devynn BreenImaging Mass Cytometry Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA.
Paul MalloryImaging Mass Cytometry Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA.ORCID 0000-0003-2266-2577
Ashley CardamoneImaging Mass Cytometry Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA.
Lois McKennettLaboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA.
Christine NewkirkImaging Mass Cytometry Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA.
Shikha SharanCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.ORCID 0000-0001-5885-7304
William BocikImaging Mass Cytometry Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, MD, USA.ORCID 0000-0002-0183-7051
Esta SterneckCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.ORCID 0000-0001-7716-8766

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Molecular Mechanisms Regulating Mouse Mammary Gland and Human Breast Tumor CellsZIABC010307 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STERNECK, GISELA · 2009 to 2025
$22.1M
Intramural NIH HHS ZIA BC010307NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Circulating tumor cells (CTCs), and especially CTC-clusters, are linked to poor prognosis and may reveal mechanisms of metastasis and treatment resistance. Therefore, developing unbiased methods for the functional characterization of CTCs in liquid biopsies is an urgent need. Here, we present an evaluation of multiplex imaging mass cytometry (IMC) to analyze CTCs in mice with human xenograft tumors. In a single-step process, IMC uses metal-labeled antibodies to simultaneously detect a large number of proteins/modifications within minimally manipulated small volumes of blood from the tail vein or heart. We used breast cancer cell lines and a patient-derived xenograft (PDX) to assess antibodies for cross-species interpretation. Along with manual verification, HALO-AI-based cell segmentation was used to identify CTCs and quantify markers. Despite some limitations regarding human-specificity, this technology can be used to investigate the effect of genetic and pharmacological interventions on the properties of single and cluster CTCs in tumor-bearing mice.

Indexed as

circulating tumor cellsimaging mass cytometryimaging-proteomicsliquid biopsyxenograft

Identifiers

PMID41509313
PMCPMC12776163

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.